Literature DB >> 33594042

Melatonin alleviates intervertebral disc degeneration by disrupting the IL-1β/NF-κB-NLRP3 inflammasome positive feedback loop.

Fan Chen1, Guowei Jiang1, Hui Liu1, Zemin Li1, Yuxin Pei2, Hua Wang1, Hehai Pan1, Haowen Cui1, Jun Long1, Jianru Wang3, Zhaomin Zheng4,5.   

Abstract

The inflammatory response is induced by the overexpression of inflammatory cytokines, mainly interleukin (IL)-1β, and is one of the main causes of intervertebral disc degeneration (IVDD). NLR pyrin domain containing 3 (NLRP3) inflammasome activation is an important source of IL-1β. As an anti-inflammatory neuroendocrine hormone, melatonin plays various roles in different pathophysiological conditions. However, its roles in IVDD are still not well understood and require more examination. First, we demonstrated that melatonin delayed the progression of IVDD and relieved IVDD-related low back pain in a rat needle puncture IVDD model; moreover, NLRP3 inflammasome activation (NLRP3, p20, and IL-1β levels) was significantly upregulated in severely degenerated human discs and a rat IVDD model. Subsequently, an IL-1β/NF-κB-NLRP3 inflammasome activation positive feedback loop was found in nucleus pulposus (NP) cells that were treated with IL-1β. In these cells, expression of NLRP3 and p20 was significantly increased, NF-κB signaling was involved in this regulation, and mitochondrial reactive oxygen species (mtROS) production increased. Furthermore, we found that melatonin disrupted the IL-1β/NF-κB-NLRP3 inflammasome activation positive feedback loop in vitro and in vivo. Melatonin treatment decreased NLRP3, p20, and IL-1β levels by inhibiting NF-κB signaling and downregulating mtROS production. Finally, we showed that melatonin mediated the disruption of the positive feedback loop of IL-1β in vivo. In this study, we showed for the first time that IL-1β promotes its own expression by upregulating NLRP3 inflammasome activation. Furthermore, melatonin disrupts the IL-1β positive feedback loop and may be a potential therapeutic agent for IVDD.

Year:  2020        PMID: 33594042     DOI: 10.1038/s41413-020-0087-2

Source DB:  PubMed          Journal:  Bone Res        ISSN: 2095-4700            Impact factor:   13.567


  57 in total

Review 1.  Non-specific low back pain.

Authors:  Chris Maher; Martin Underwood; Rachelle Buchbinder
Journal:  Lancet       Date:  2016-10-11       Impact factor: 79.321

Review 2.  What low back pain is and why we need to pay attention.

Authors:  Jan Hartvigsen; Mark J Hancock; Alice Kongsted; Quinette Louw; Manuela L Ferreira; Stéphane Genevay; Damian Hoy; Jaro Karppinen; Glenn Pransky; Joachim Sieper; Rob J Smeets; Martin Underwood
Journal:  Lancet       Date:  2018-03-21       Impact factor: 79.321

Review 3.  The Epidemiology of low back pain.

Authors:  D Hoy; P Brooks; F Blyth; R Buchbinder
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-12       Impact factor: 4.098

Review 4.  Programmed cell death in intervertebral disc degeneration.

Authors:  Chang-Qing Zhao; Lei-Sheng Jiang; Li-Yang Dai
Journal:  Apoptosis       Date:  2006-12       Impact factor: 4.677

Review 5.  Glycosaminoglycan synthesis in the nucleus pulposus: Dysregulation and the pathogenesis of disc degeneration.

Authors:  Elizabeth S Silagi; Irving M Shapiro; Makarand V Risbud
Journal:  Matrix Biol       Date:  2018-03-01       Impact factor: 11.583

6.  Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010.

Authors:  Gonghuan Yang; Yu Wang; Yixin Zeng; George F Gao; Xiaofeng Liang; Maigeng Zhou; Xia Wan; Shicheng Yu; Yuhong Jiang; Mohsen Naghavi; Theo Vos; Haidong Wang; Alan D Lopez; Christopher J L Murray
Journal:  Lancet       Date:  2013-06-08       Impact factor: 79.321

Review 7.  Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix.

Authors:  Peter J Roughley
Journal:  Spine (Phila Pa 1976)       Date:  2004-12-01       Impact factor: 3.468

Review 8.  Cell death in intervertebral disc degeneration.

Authors:  Fan Ding; Zeng-wu Shao; Li-ming Xiong
Journal:  Apoptosis       Date:  2013-07       Impact factor: 4.677

9.  The global burden of low back pain: estimates from the Global Burden of Disease 2010 study.

Authors:  Damian Hoy; Lyn March; Peter Brooks; Fiona Blyth; Anthony Woolf; Christopher Bain; Gail Williams; Emma Smith; Theo Vos; Jan Barendregt; Chris Murray; Roy Burstein; Rachelle Buchbinder
Journal:  Ann Rheum Dis       Date:  2014-03-24       Impact factor: 19.103

Review 10.  Prevention and treatment of low back pain: evidence, challenges, and promising directions.

Authors:  Nadine E Foster; Johannes R Anema; Dan Cherkin; Roger Chou; Steven P Cohen; Douglas P Gross; Paulo H Ferreira; Julie M Fritz; Bart W Koes; Wilco Peul; Judith A Turner; Chris G Maher
Journal:  Lancet       Date:  2018-03-21       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.